The latest price target for Silence Therapeutics (NASDAQ:SLN) was reported by Morgan Stanley on June 28, 2024. The analyst firm set a price target for $49.00 expecting SLN to rise to within 12 months (a possible 130.05% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Silence Therapeutics (NASDAQ:SLN) was provided by Morgan Stanley, and Silence Therapeutics maintained their overweight rating.

There is no last upgrade for Silence Therapeutics

There is no last downgrade for Silence Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.

While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a maintained with a price target of $45.00 to $49.00. The current price Silence Therapeutics (SLN) is trading at is $21.30, which is out of the analyst’s predicted range.